Faron Pharmaceuticals Oy New data published by Clinical Cancer Research
13 February 2019 - 7:57PM
RNS Non-Regulatory
TIDMFARN
Faron Pharmaceuticals Oy
13 February 2019
Faron Pharmaceuticals Ltd
("Faron" or the "Company")
Potential of Clever-1 blockade in cancer monotherapy and in
combination with PD-1 checkpoint inhibition
- New data published by Clinical Cancer Research
TURKU - FINLAND, 13 February 2019 - Faron Pharmaceuticals Ltd
("Faron") (LON: FARN), the clinical stage biopharmaceutical
company, today announces new data supporting the immunotherapeutic
blockade of Clever-1 as an alternative to, or in combination with,
PD-1 checkpoint inhibition to reactivate immunity against
immunosuppressive tumours. The research, in which modulation of
Clever-1 was investigated in multiple mouse cancer models, was
published online in Clinical Cancer Research, a journal of the
American Association for Cancer Research.
The research, conducted by Miro Viitala and colleagues at the
University of Turku, Finland, part of Faron's scientific network,
supports the rationale behind Faron's development of Clevegen, its
fully human anti-Clever-1 antibody in clinical development, as a
potential immunotherapy for cancer treatment.
Overcoming cancer-related immunosuppression presents a
significant obstacle to successful cancer treatment. The
researchers describe the molecular pathway by which Clever-1
controls the immunosuppressive activities of tumour-associated
macrophages and report that a genetic deficiency of macrophage
Clever-1 in multiple mouse models led to significant C8+ T cell
activation and impairment of solid tumour growth. Comparable
results were also seen during immunotherapeutic anti-Clever-1
treatment.
Notably, a synergistic anti-tumour benefit was identified when
immunotherapeutic blockade of Clever-1 was combined with PD-1
checkpoint inhibition but, compared to anti-PD-1 therapy,
anti-Clever-1 did not lead to T cell exhaustion. This further
supports the clinical evaluation of Clever-1 targeting as a novel
cancer treatment strategy and the potential of Clevegen to be used
both as a standalone immunotherapy and in combination with other
cancer therapies.
Dr Markku Jalkanen, Chief Executive Officer of Faron, said: "We
are very pleased about these published results by Faron's
scientific network. We believe that the next significant step in
cancer treatment is based on biomarker-guided use of selective
immunotherapeutic drugs, alone or in combination. Faron's
investigational immunotherapeutic, Clevegen, provides a unique new
feature to these options by removing immune suppression from the
tumour environment and potentially increasing efficacy of
immunotherapy checkpoint molecules. We hope to see supportive
biomarker changes in our MATINS trial patients during the first
half of 2019 while we advance development of Clevegen as a novel
therapy for patients with currently untreatable solid cancers."
Following Faron's participation in the funding of this research
work, the Company has filed a new patent application for the
combined use of Clevegen and immunotherapy checkpoint inhibitors to
treat cancer.
Cited reference: Viitala M, Virtakoivu R, Tadayon S, Rannikko J,
Jalkanen S and Hollmén M. Immunotherapeutic blockade of macrophage
Clever-1 reactivates the CD8+ T cells against immunosuppressive
tumors. Clinical Cancer Research on line code:
DOI:10.1158/1078-0432.CCR-18-3016 and link:
http://clincancerres.aacrjournals.org/cgi/content/abstract/1078-0432.CCR-18-3016
For more information please contact:
Faron Pharmaceuticals Ltd
Dr Markku Jalkanen, Chief Executive Officer
investor.relations@faron.com
Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Lindsey Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com
Westwicke Partners, IR (US)
Chris Brinzey
Phone: 01 339 970 2843
E-Mail: chris.brinzey@westwicke.com
Panmure Gordon (UK) Limited, Nomad and Broker
Emma Earl, Freddy Crossley
Phone: +44 207 886 2500
About Faron Pharmaceuticals Ltd
Faron (AIM:FARN) is a clinical stage biopharmaceutical company
developing novel treatments for medical conditions with significant
unmet needs. The Company currently has a pipeline focusing on acute
organ traumas, vascular damage and cancer immunotherapy. The
Company's lead candidate Traumakine, to prevent vascular leakage
and organ failures, is currently the only treatment for Acute
Respiratory Distress Syndrome (ARDS) in Phase III clinical stage.
There is currently no approved pharmaceutical treatment for ARDS,
even though this syndrome has very high mortality (30-40%) and high
health care costs. An additional European Phase II Traumakine trial
is underway for the Rupture of Abdominal Aorta Aneurysm ("RAAA").
Faron's second candidate Clevegen is a ground breaking early
clinical anti-Clever-1 antibody. Clevegen has the ability to switch
immune suppression to immune activation in various conditions, with
potential across oncology, infectious disease and vaccine
development. This novel macrophage-directed immuno-oncology switch
called Turn-on-your-Immunity or Turn-It may be used alone or in
combination with other immune checkpoint molecules for the
treatment of cancer patients. Faron is based in Turku, Finland.
Further information is available at www.faron.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRACKNDPFBKKBBD
(END) Dow Jones Newswires
February 13, 2019 03:57 ET (08:57 GMT)
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Apr 2024 to May 2024
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From May 2023 to May 2024